the impact of high and low burden tp53 mutations on risk and treatment decision in cll
Published 4 weeks ago • 156 plays • Length 4:31Download video MP4
Download video MP3
Similar videos
-
1:07
testing for ighv and tp53 mutations to guide treatment decisions in cll
-
1:21
identifying low-burden tp53 mutations with ngs in cll
-
2:12
the impact of genetic abnormalities on treatment decisions in cll
-
2:02
the prognostic impact of tp53 and ighv status in the era of targeted therapies in cll
-
1:04
defining high-risk cll: known and emerging mutations
-
11:29
impact of bvf on valve durability/integrity - #tct2022
-
2:31
what is the prognosis of cll?
-
4:19
cll: what is 'watch & wait' and what can a patient do during this phase?
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
2:54
the definition of high-risk cll
-
1:38
the importance of tp53 in cll
-
1:36
the impact of tp53 mutation on treatment approaches in mcl
-
2:08
defining high-risk disease in cll
-
2:08
disease characteristics impacting treatment decisions in cll
-
2:24
the challenges of treating tp53-mutated aml and mds
-
1:26
the role of tp53 in cll
-
2:08
an insight into the current understanding of risk factors for cll
-
2:36
treatment approaches to cll with high-risk molecular features
-
2:48
debulking strategies in cll before venetoclax therapy
-
0:58
updates on the eric recommendations for immunoglobulin gene sequence analysis in cll
-
1:56
the future of fixed-duration therapy in cll
-
0:56
the current treatment landscape in cll